Intelligence Profile
Research Papers
Based on the available evidence, retatrutide is a novel triple receptor agonist being studied for type 2 diabetes and obesity treatment. Here's what the current research shows:
Clinical Trial Evidence
Several clinical trials are examining retatrutide's effects across different populations:
- TRANSCEND-T2D-1 (NCT06354660): A completed Phase 3 trial comparing retatrutide to placebo in adults with type 2 diabetes who had inadequate blood sugar control with diet and exercise alone
- Obesity and cardiovascular disease study (NCT05882045): An active Phase 3 trial studying retatrutide in participants with obesity and existing heart disease
- Smaller Phase 1 studies have examined drug interactions (with metoprolol) and kidney function effects in healthy participants and those with impaired kidney function
Research Findings
Recent systematic reviews and meta-analyses have begun incorporating retatrutide data:
- A 2026 systematic review examined retatrutide's effects on blood pressure and cholesterol levels by pooling data from randomized controlled trials
- Network meta-analyses comparing obesity treatments and incretin-based diabetes therapies have included retatrutide alongside other medications
- A narrative review discussed retatrutide as part of the emerging class of triple agonist medications for adolescent obesity
Preclinical Research
Animal studies have explored retatrutide's effects beyond metabolism, including one study examining learning and memory effects in diabetic rats.
Safety Considerations
The research literature includes discussions of safety monitoring, with at least one report examining potential adverse events associated with unapproved use.
Important note: This summary is for informational purposes only and should not replace consultation with healthcare providers. Clinical trial results may not yet be fully published, and approved prescribing information should be consulted for current safety and efficacy data.
The evidence base appears to be growing rapidly, with multiple Phase 3 trials recently completed or ongoing, suggesting retatrutide is in late-stage development.